Rapivab® (peramivir) – Expanded indication
January 28, 2021 - The FDA approved Biocryst’s Rapivab (peramivir), for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
Download PDF
